Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs propofol for postoperative quality of recovery in ESRD patients
ChiCTR2200061835Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in end-stage kidney disease (ESKD) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: QoR-15 score on postoperative day 1. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2200061835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061835.